

Brand Name: Daliresp/Daxas

Generic: roflumilast


Type: small molecule

Year Accepted/Phase: 2011

Mechanism:

Roflumilast works by inhibiting the enzyme phosphodiesterase-4 (PDE4), which reduces the production of inflammatory mediators in the lungs, leading to reduced inflammation and improved lung function.

Chemical Structure:



Indication:

Daliresp/Daxas (roflumilast) is indicated for the treatment of severe COPD associated with chronic bronchitis and a history of exacerbations.

Clinical trials:

Clinical Trials for COPD

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/26792988/>

Purpose: Evaluate the efficacy and safety of roflumilast in patients with severe COPD.

Dates: Clinical trials for roflumilast in COPD were conducted in the 2000s.

Results: These trials demonstrated that roflumilast reduced the rate of exacerbations in patients with severe COPD, improved lung function, and quality of life.

Impact: The positive results from these trials supported the approval of roflumilast for the treatment of severe COPD.